CRISPR Therapeutics Revenue (Quarterly YoY Growth) View 4,000+ financial data types. Get the detailed quarterly/annual income statement for CRISPR Therapeutics AG (CRSP). Long-Term Debt to Equity for the company is recorded at 4.69, with the Long-Term Debt to Total Capital now at 4.44. CRISPR Therapeutics AG is a Swiss-American biotechnology company headquartered in Zug. The top three institutional holders of CRSP stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 8,457,320, which is approximately 30.449% of the company’s market cap and around 1.30% of the total institutional ownership; CAPITAL INTERNATIONAL INVESTORS, holding 7,394,274 shares of the stock with an approximate value of $898.77 million in CRSP stocks shares; and NIKKO ASSET MANAGEMENT AMERICAS, INC., currently with $449.45 million in CRSP stock with ownership of nearly -0.385% of the company’s market capitalization. CRISPR Therapeutics AG (CRSP – Free Report) reported fourth-quarter 2020 loss per share of $1.50, wider than the Zacks Consensus Estimate of a loss of $1.23.However, the company had reported earnings of 51 cents per share in the year-ago quarter. The mentioned changes placed institutional holdings at 47,399,773 shares, according to the latest SEC report filing. In fiscal year 2019, the company had revenues of $289.59 million, with net income of $66.86 million. CRISPR Therapeutics's key executives are Samarth Kulkarni, Steve Caffé and Shaun Foy. Return on Equity for this stock inclined to 10.04, with Return on Assets sitting at 8.59. The company... Nexstar Media Group Inc. traded at a high on 02/23/21, posting a 9.21 gain after which it closed the day’ session at $140.33.... Cimarex Energy Co. jumped around 5.01 points on Tuesday, while shares priced at $57.02 at the close of the session, up 9.63%. Start your Free Trial. With the latest financial reports released by the company, CRISPR Therapeutics AG posted 0.51/share EPS, while the average EPS was predicted by analysts to be reported at -0.63/share. The Average True Range (ATR) for CRISPR Therapeutics AG is set at 5.67, with the Price to Sales ratio for CRSP stock in the period of the last 12 months amounting to 100.41. CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020, at 9:30 a.m. Crispr Therapeutics Down 4% On Earnings Miss; Street Stays Bullish lundi, 27 juillet 2020 zacks. Vous pouvez modifier vos choix à tout moment dans vos paramètres de vie privée. The Price to Book ratio for the last quarter was 6.35, with the Price to Cash per share for the same quarter was set at 21.36. Pour autoriser Verizon Media et nos partenaires à traiter vos données personnelles, sélectionnez 'J'accepte' ou 'Gérer les paramètres' pour obtenir plus d’informations et pour gérer vos choix. Nos partenaires et nous-mêmes stockerons et/ou utiliserons des informations concernant votre appareil, par l’intermédiaire de cookies et de technologies similaires, afin d’afficher des annonces et des contenus personnalisés, de mesurer les audiences et les contenus, d’obtenir des informations sur les audiences et à des fins de développement de produit. Browse... View Full Chart Revenue (TTM) Chart . Latest CRISPR Therapeutics annual … Get the hottest stocks to trade every day before the market opens 100% free. Start your Free Trial. Seagen beats CRISPR Therapeutics on 10 of the 14 factors compared between the two stocks. The... You have entered an incorrect email address! When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 181.00%. Export Data Save Image Print Image For advanced charting, view our full-featured Fundamental Chart. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresse IP, Navigation et recherche lors de l’utilisation des sites Web et applications Verizon Media. Seagen is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks. Year-over-year growth is forecast to reach -99.1% down from the last financial year. CRISPR Therapeutics AG [CRSP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.27. We do not sell or share your information with anyone. CRISPR Therapeutics AG Annual stock financials by MarketWatch. The two companies... OCUL stock: Ocular Therapeutix (OCUL) Is Better Than You Think, The Goodyear Tire & Rubber Company (GT): Keeping an Eye On The Long Term. Revenue: Total collaboration revenue was $0.1 million for the third quarter of 2020 compared to $211.9 million for third quarter of 2019, which ... CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law. Click here now. What is CRISPR Therapeutics revenue? This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy. In the same year, the number of employees stood at 304. Browse... View Full Chart Revenue (Quarterly YoY Growth) Chart . CRISPR THERAPEUTICS® word mark and design logo, … Even if you’re not actively in crypto, you deserve to know what’s actually going on... The company report on November 24, 2020 that CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRSP shares is $102.63 per share. Precedence Research has been monitoring the CRISPR and Cas Genes Market Size and is expected to generate US$ 4.23 billion by 2027, witnessing a … CRISPR Therapeutics has lower revenue, but higher earnings than Seagen. CRISPR Therapeutics AG Condensed Consolidated Statements of Operations (Unaudited, In thousands except share data and per share data) Three Months Ended December 31, Year Ended December 31, 2020: 2019: 2020: 2019: Revenue: Collaboration revenue $ 194 $ 77,016 $ 543 $ 289,590: Grant revenue: 176 — 176 — Total revenue $ 370 $ 77,016: 719 $ 289,590: Operating … CRISPR Therapeutics has established a portfolio of therapeutic … Save my name, email, and website in this browser for the next time I comment. Additionally, 122 investors decreased positions by around 4,673,961 shares, while 56 investors held positions by with 29,914,080 shares. Following the latest upgrade, the current consensus, from the 15 analysts covering CRISPR Therapeutics, is for revenues of US$15m in 2021, which would reflect a painful 80% reduction in CRISPR Therapeutics' sales over the past 12 months. . The current RSI for CRSP stock in for the last two-week period is set at 74.92, with the RSI for the last a single of trading hit 82.45, and the three-weeks RSI is set at 68.66 for CRISPR Therapeutics AG [CRSP]. Start Your Free Trial. CRISPR Therapeutics EPS misses by $0.23, misses on revenue SA News Tue, Feb. 16 33 Comments CRISPR Therapeutics AG SEC Filing - Annual Report (10-K) February 16, 2021 The rating firms predict current quarter revenue for CRISPR Therapeutics AG will drop -349%, while the growth in revenue is estimated to hit -16.5% for the next quarter. © DBT NEWS PVT. An RSI rate of 50 would represent a neutral market momentum. Join now to get the NewsHeater.com pre-market morning brief 100% free. Market cap of AMCI Acquisition Corp. [AMCI] reaches 214.85M – now what? With this latest performance, CRSP shares gained by 28.34% in over the last four-week period, additionally plugging by 82.53% over the last 6 months – not to mention a rise of 78.46% in the past year of trading. In November 2019, CRISPR Therapeutics and its partner Vertex announced positive, interim data from the first two patients with severe hemoglobinopathies - one patient with transfusion-dependent beta thalassemia (TDT) and one patient with severe sickle cell disease (SCD) - treated with the investigational CRISPR/Cas9 gene-editing therapy CTX001 in the ongoing Phase 1/2 … Aptinyx Inc. [APTX] Stock trading around $3.81 per share: What’s Next? CRSP Stock saw the intraday high of $124.43 and lowest of $110.355 per share.

Bazaar Kannada Movie Release Date, Burger Ranch Fry Sauce Recipe, Our Best Frozen Meatballs, 2000 Thread Count Sheets Price, Milledgeville Ga Schools,